Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal cancer who have progressed after first-line oxaliplatin-based chemotherapy plus bevacizumab.
Advanced Colorectal Cancer
DRUG: regorafenib
the rate of evaluable patients alive and not progressed at 6 months, 6 months
worst grade toxicity per patient, evaluated according to RECIST 1.1, every 4 weeks up to 1 year|number of patients with complete plus partial response, 6 months|progression free survival, the time from registration to progression or death without progression, up to one year|overall survival, as the time from registration to the date of death due to any cause, up to 2 years
The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal cancer who have progressed after first-line oxaliplatin-based chemotherapy plus bevacizumab.